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Abstract
the  incidence  of  nosocomial  pneumonia  involving
methicillin-resistant  Staphylococcus  aureus strains
(MRsa)  is  on  the  rise  worldwide.  for  years,  van-
comycin has been used as the drug of choice in the
treatment of MRsa infections and was recommended
as  such  by  clinical  guidelines.  there  is  growing  evi-
dence that vancomycin, despite low resistance rates is
a suboptimal therapeutic option in critically ill patients,
particularly in patients with pneumonia. disadvantages
of vancomycin are i) slow bactericide action, ii) poor
penetration  into  pulmonary  tissue,  iii)  the  globally
slowly increasing vancomycin MIcs (“creep”) that re-
sult in increased clinical failure despite being suscepti-
ble according to defined break points and iv) nephro-
toxicity.  In  contrast  to  other  novel  antibiotics  with
MRsa activity, linezolid is currently approved for the
treatment of nosocomial pneumonia in the usa and
Europe.  several  studies  have  compared  vancomycin
with  linezolid  for  nosocomial  pneumonia  with  con-
flicting results. this review compares both substances
regarding  pharmacodynamics,  resistance,  safety  and
clinical efficacy and discusses preliminary data of the
zEPHyR study. this study compared linezolid versus
vancomycin in patients with proven MRsa pneumonia
and was the largest trial ever conducted in this popula-
tion. 
NosocoMIal PNEuMoNIa – dEfINItIoNs,
EPIdEMIology aNd PatHogENs
Pneumonia is defined as being nosocomial or hospital-
acquired (HaP) if it becomes apparent >48 h after ad-
mission to the hospital [1]. Pneumonia in ventilated
patients is defined as ventilator- associated pneumonia
(VaP) and considered as a subset of HaP. the risk of
developing pneumonia is particularly high in patients
requiring mechanical ventilation. In intensive care pa-
tients,  pneumonia  is  the  most  common  hospital-ac-
quired infection. according to data of the European
point-prevalence study EPIc , nosocomial pneumonia
accounts for 47% of all Icu-acquired infections [2].
during the past two decades, gram-positive bacte-
ria (mostly staphylococci and enterococci) have been
becoming  increasingly  prevalent  in  the  spectrum  of
nosocomial  pathogens  besides  gram-negative  bacte-
ria. among gram-positives, enterococci are not con-
sidered to be a relevant pathogen in pneumonia but
rather colonizers [3]. this increase in gram-positive
bacteria is related to demographic changes as well as
to an increase in the number of high-risk patients and
intensive care measures. Extensive use of broad-spec-
trum  antibiotics  with  predominantly  gram-negative
coverage  and  the  emergence  of  multi-drug  resistant
staphylococci and enterococci in the community set-
ting further contribute to this trend [2]. 
according to the data of the KIss study performed
in germany, gram-positive pathogens cause a major
fraction  of  nosocomial  pneumonias,  Staphylococcus
aureus being the most important pathogen in ventila-
tor-associated pneumonia, followed by Pseudomonas
aeruginosa,  Klebsiella  pneumoniae  and  Escherichia
coli [4]. of note, in that large study (n = 16,351) there
was no difference in the rank of pathogens between
early onset HaP (up to day 4 after hospitalization) and
late onset VaP. Predictabilities of the occurrence of
pathogens  were  similar  and  independent  on  pre-de-
fined time frames for “early” and “late” onset.
tHE clINIcal PRoBlEM
Primarily due to issues in definition, the exact attribu-
tive  mortality  of  HaP  remains  a  matter  of  debate.
However, it has been confirmed by large observational
studies that pneumonia is the major cause of sepsis [5,
6].  sepsis  can  progress  to  severe  sepsis  and  septic
shock, which is associated in a drastic rise in mortality
[7]. thus, early and appropriate treatment of infection
should interrupt this progression and improve patient
outcome.  Indeed,  clinical  studies  have  univocally
shown for both, sepsis and HaP, that i) inadequate
(i.e. insufficient level of agent at the site of infection)
[8],  ii)  inappropriate  (i.e.  not  covering  the  right
pathogen or pathogen resistant to agent) [9] or iii) de-
layed antimicrobial therapy [10, 11] is associated with
increased  pneumonia  mortality  as  well  as  increased
length of hospital stay and costs [12].
a recent study by Kumar et al. investigating 5,715
patients with septic shock (leading focus pneumonia)
in three countries found that Staphylococcus aureus was
the  leading  individual  bacterial  pathogen  accounting
for  20%  of  all  cases  of  inappropriate  antimicrobial
treatment, which was associated with dramatic decrease
in  survival  [13].  Staphylococcus  aureus was  the  only
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1 Pletz##_Umbruchvorlage  23.11.10  11:55  Seite 507pathogen that correlated with mortality in a multiple
logistic regression analysis carried out in a large retro-
spective cohort study of inpatients with culture-posi-
tive pneumonia in the usa [14]. MRsa is growing in
prevalence  and  is  now  endemic  in  many  healthcare 
facilities  and  communities  [15].  In  2003,  >60%  of
Staphylococcus  aureus isolates  from  us-Icus  were 
methicillin-resistant  [16].  In  Europe,  there  is  a 
North to south trend in the proportion of s. aureus
that  is  methicillin-  resistant,  ranging  from  0%  in 
northern  European  countries  to  >50%  in  more 
southern  countries  (European  antimicrobial  Resis-
tance  surveillance  system.  EaRss  annual  Report
2007.  Bilthoven,  the  Netherlands:  EaRss; 2008.
http://www.rivm.nl/earss/Images/EaRss%202007
fINal  tcm61-55933.pdf  [accessed  17  March  2010].
some strains of MRsa, particularly those of commu-
nity origin [community-acquired MRsa (ca-MRsa)],
produce the Panton–Valentine leukocidin (PVl) toxin,
which is associated with necrotizing infections, often in
previously  healthy  individuals  [17].  PVl-producing
strains may become of increasing importance if ca-
MRsa strains continue to invade the hospital setting
but they will not be discussed further in this article in
order to maintain a focus on nosocomial pneumonia in
which PVl-producing strains are much less prevalent.
VaNcoMycIN
Background:  Vancomycin is a glycopeptide antibiotic
that disrupts cell wall synthesis in gram-positive bac-
teria  by  inhibiting  peptidoglycan  biosynthesis.  an
auc/MIc ratio of ≥400 has been advocated as a tar-
get to achieve clinical effectiveness with vancomycin.
animal  studies  and  limited  human  data  appear  to
demonstrate that vancomycin is not concentration de-
pendent and that the auc/MIc is a predictive phar-
macokinetic parameter for vancomycin for review see
[18]. 
Pros: Vancomycin is currently (still) the treatment of
choice  in  MRsa  pneumonia.  therefore  it  served  as
comparator in most phase III MRsa pneumonia trials.
complete resistance to vancomycin is conferred by the
vana determinant and has yet been detected only in
individual patients [19]. 
Cons:  However,  there  are  some  clinically  important
disadvantages regarding the use of vancomycin for the
treatment of pneumonia:
i)  MIcs have been observed to be increasing over
time (MIc creep) [20, 21]. such isolates are still con-
sidered to be susceptible per definition since the MIc
is  below  defined  breakpoints.  Nonetheless,  relation-
ship between increased MIc and treatment success or
failure in serious Staphylococcus aureus infections has
recently been established. failure rates exceeding 60%
for  Staphylococcus  aureus displaying  a  vancomycin
MIc value of 4 mg/l prompted recommendations in
2006 from the clinical and laboratory standards In-
stitute to lower the breakpoint for susceptibility from
4 to 2 mg/l and in 2008 from the us food and drug
administration. Meanwhile, a number of studies have
established a relationship between vancomycin treat-
ment  failures  and  infections  in  patients  with  methi-
cillin-resistant Staphylococcus aureus displaying an MIc
of 2mg/l (for review see [22, 23]. this trend has urged
the Idsa to issue ”Vancomycin therapeutic guide-
lines” that recommend to aim for trough serum van-
comycin concentrations of 15–20 mg/ and to main-
tain trough serum vancomycin concentrations always
>10  mg/l  to  avoid  the  development  of  resistance.
further, alternative treatment is recommended for iso-
lates with MIc>2mg/l, because a targeted auc/MIc
of 400 is not achievable with conventional dosing [22]. 
ii)    Vancomycin  penetrates  poorly  into  the  lung,
only <12 % of plasma levels [24] are detected in pul-
monary  epithelial  lining  fluid  at  therapeutic  doses
which is associated with pneumonia treatment failure
despite the in vitro susceptibility of the bacterial iso-
lates [25-27].
iii)    Vancomycin  is  considered  slowly  bactericidal
according to in vitro killing curves [28].
iv)  Vancomycin is associated with nephrotoxicity
and ototoxicity, although the frequency of these ad-
verse reactions was higher in early reports and is at-
tributed to the low purity of early formulations [29].
Nephrotoxicity due to vancomycin is of great concern
due to the contribution of acute kidney injury to poor
clinical outcome in critically ill patients in the Icu, a
population particularly vulnerable to MRsa infection
[30-33].  In  addition,  the  recently  recommended  in-
creased  through  levels  are  associated  with  increased
nephrotoxicity.
the  disadvantages  of  vancomycin  can  in  part  be
compensated  by  adding  a  second  antibiotic  with
MRsa  activity  and  good  tissue  penetration,  e.g.  ri-
fampin.  In  vitro studies  have  suggested  a  synergism
between vancomycin and rifampin [34, 35]. combina-
tion of vancomycin with rifampin has been used since
the 1970s [36] and has been advocated by some opin-
ion leaders despite the lack of data from randomized
controlled trials (Rct). Recently, the first Rct from
Korea with 83 enrolled cases demonstrated superiority
of vancomycin/rifampin versus vancomycin alone in
patients with MRsa pneumonia: the clinical cure rate
in the modified intention-to-treat population was 53.7
% (22 of 41) in the vancomycin plus rifampin group,
and 31.0 % (13 of 42) in the vancomycin-only group
(p = .047) [37, 38]. However, it has to be considered
that resistance to rifampin evolves easily and broad use
of this combination may result in a fast increase of re-
sistance to rifampin. another drawback of rifampin is
drug interactions that limit its use in critically ill pa-
tients and patients under immunosuppressive therapy.
lINEzolId
Background. linezolid is the first oxazolidinone avail-
able for clinical use [39]. It inhibits bacterial protein
synthesis  via  a  new  mechanism.  While  macrolides,
tetracyclines, and aminoglycosides inhibit the elonga-
tion of already initiated peptide chains, linezolid pre-
vents the initiation of protein synthesis by blocking the
assembly  of  a  functional  initiation  complex.  this
mechanism  of  action  precludes  cross-resistance  with
other protein synthesis inhibitors (for review see [40].
In vitro studies have shown that the antibacterial activi-
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time-dependent with auc/MIc as the best parameter
predicting the in-vivo efficacy [41, 42]. linezolid has
activity  against  gram-positive  pathogens,  including
bacteriostatic in vitro activity for staphylococci, but has
limited activity against gram-negative bacteria [43].
Pros:  linezolid  is  besides  vancomycin  currently  the
only of the novel drugs with MRsa-activity that is ap-
proved for the treatment of nosocomial pneumonia in
the  usa  and  Europe,  including  cases  caused  by
MRsa. In the usa it represents the only alternative to
vancomycin for this indication [23]. Pulmonary pene-
tration of linezolid is good: 415 % of plasma levels
were recovered in epithelial lining fluid [44].
In contrast to other antibacterial drugs used in the
treatment  of  severe  gram-positive  infections  (gly-
copeptides,  lipoglycopeptides,  quinupristin/dalfo-
pristin,  daptomycin,  tigecycline,  cephalosporins  with
MRsa-activity),  linezolid  is  available  for  both  intra-
venous and oral administration. the bioavailability of
oral formulations approaches 100 % [45], while food
has no relevant effect on drug exposition. the elimi-
nation half-life is in the 4 to 5 h range requiring twice
daily  administration.  standard  dosages  are  600  mg
q12h  for  both  intravenous  and  oral  administration.
there is a slight, probably not clinically relevant accu-
mulation after oral administration [46].
Resistance was first observed in a clinical Staphylo-
coccus  aureus isolate  in  2001  [47],  although  the
lEadER surveillance program has shown that 99.55
% of isolates remained susceptible to linezolid in the
usa in 2006 [48].
Cons: thrombocytopenia is a commonly observed ad-
verse  reaction  to  linezolid  therapy,  with  occurrence
rates of around 30 % [49-51], a rate much higher than
that reported in phase 3 trials [43]. thrombocytopenia
is more common following prolonged treatment (>14
days) and in patients with renal insufficiency [50, 52].
the inhibition of mitochondrial protein synthesis by
linezolid - studied in one case by de Vriese - can result
in potentially severe clinical effects including optic/pe-
ripheral  neuropathy  and  lactic  acidosis  [53].  these
events are not frequently observed and are mostly re-
versible following termination of linezolid treatment,
but  there  are  reports  of  severe  irreversible  effects,
such as permanent blindness, in patients treated only
for  a  short  time  [54].  as  a  reversible,  non-selective
monoamine oxidase inhibitor, linezolid in combination
with  serotonergic  agents  has  been  associated  with
serotonin syndrome [55]. the linezolid licence recom-
mends that treatment should be restricted to a maxi-
mum of 28 days [43].
lINEzolId VERsus VaNcoMycIN IN
PNEuMoNIa – INcoNclusIVE REsults of
tRIals aNd MEta-aNalysEs lEad to
dIffERENt REcoMMENdatIoNs By
guIdElINEs
two retrospective subgroup analyses of ventilated and
non-ventilated  patients  with  MRsa  [56,  57]  from
nosocomial pneumonia clinical trials [58, 59] showed
that linezolid-treated patients had higher survival and
clinical cure rates than vancomycin-treated patients. It
has  been  suggested  that  this  may  be  due  to  the
favourable  intrapulmonary  distribution  of  linezolid
[60]. However, the viability and validity of these sub-
set analyses has been questioned [61, 62], such that
further trials are required before linezolid can be rec-
ommended to be used preferentially over vancomycin
for the treatment of MRsa pneumonia. a recent trial
of patients with MRsa-VaP, which was designed and
powered to demonstrate “non-inferiority” of linezolid
to vancomycin demonstrated numerically better values
for  linezolid-treated  patients  compared  with  van-
comycin-treated patients with respect to microbiologi-
cal eradication (56.5 % and 47.4 %, respectively), clini-
cal cure (66.7 % and 52.9 %, respectively), survival rate
(86.7 % and 70.0 %, respectively) and length of hospi-
talization (18.8 and 20.1 days, respectively), ventilation
(10.4 and 14.3 days, respectively) and Icu stay (12.2
and 16.2 days, respectively) [63]. for the small number
of  subjects  in  this  study  these  differences  were  not
statistically significant.
a recent meta-analysis including 9 trials comparing
glycopeptides (7 vancomycin and 2 teicoplanin) with
linezolid found that the linezolid versus glycopeptide
analysis showed a clinical cure relative risk of 1.01 (95
% confidence interval, 0.93-1.10; p = .83; I(2) = 0 %)
and a microbiological eradication relative risk of 1.10
(95 % confidence interval, 0.98 -1.22; p = 0.10) [64].
In contrast, they found that the risks of thrombocy-
topenia (relative risk, 1.93; 95 % confidence interval,
1.30-2.87; p = 0.001) and gastrointestinal events (rela-
tive risk, 2.02; 95 % confidence interval, 1.10-3.70; p =
0.02) were higher with linezolid, but they did see no
differences for renal dysfunction or all-cause mortality
(relative risk, 0.95; 95 % confidence interval, 0.76-1.18;
p = 0.63). the authors therefore concluded that line-
zolid was not superior to vancomycin in pneumonia.
However, only 3 of these studies enrolled exclusively
patients with pneumonia [64]. 
despite using the same trials for calculation, a sec-
ond meta-analysis found also no difference in treat-
ment success for patients pneumonia (oR=1.16, 95 %
cI 0.85-1.57) but a trend for better eradication rates in
all  microbiologically  assessed  patients  for  linezolid
(oR=1.33, 95 % cI 1.03-1.71). In contrast to Kalil et
al.  they  found  no  difference  in  total  adverse  effects
(oR=1.14, 95% cI 0.82-1.59) but more nephrotoxici-
ty  in  patients  receiving  vancomycin  (oR=0.31,  95%
cI 0.13-0.74) [65].
as clinical data on linezolid in HaP/VaP are in-
conclusive  so  are  the  recommendations  of  current
guidelines.  the  ats/Idsa  guideline  on  HaP/VaP
does not advocate to preferred use of linezolid in pa-
tients  with  HaP/VaP  [1].  In  contrast,  the  german
sepsis  guideline  recommends  linezolid  in  proven
MRsa pneumonia and expressively warns to rely on
vancomycin mono-therapy in such cases [66]. 
zEPHyR study
In order to resolve these questions Pfizer initiated a –
probably final – international phase 4 study to com-
pare  linezolid  to  vancomycin  for  the  treatment  of
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complete  results  of  that  study  have  not  been  pub-
lished  yet,  but  preliminary  results  were  presented  at
the 48th annual Meeting of the Infectious diseases
society of america (Idsa) in Boston on october 23,
2010 by Jean chastre (abstract #5047). the zEPHyR
(linezolid in the treatment of subjects with nosoco-
mial pneumonia proven to be due to methicillin-resis-
tant Staphylococcus aureus) study was the largest ever
conducted in this population. the study was designed
as non-inferiority trial with nested superiority hypoth-
esis. 
Investigators from 156 centers worldwide random-
ized 1,225 patients, of whom 448 patients had proven
MRsa  nosocomial  pneumonia  (modified  intent-to-
treat group); 339 patients also met key protocol crite-
ria at the end of study (per-protocol group) and were
included in the primary analysis. In the per protocol
group, 125 patients treated with linezolid (68.3 %) and
140 (74.5 %) treated with vancomycin were ventilated
at baseline. Mean vancomycin through level on day 3
was 14.1mg/l (95 % cI 2.8-50.8 %; n = 140). Interest-
ingly, clinical response rates in the mItt were not in-
fluenced by vancomycin through levels. clinical suc-
cess  rates  at  the  end  of  study  were  57.6  percent
(95/165) for patients treated with linezolid compared
with 46.6 percent (81/174) for patients treated with
vancomycin  in  the  per-protocol  group,  the  primary
endpoint.  these  results  demonstrated  that  linezolid
achieved a statistically significantly higher clinical suc-
cess rate compared to vancomycin (95 % cI for the
difference in response rates: 0.5 %, 21.6 %; p = 0.042).
Results were consistent for the per-protocol group at
end of treatment and for all MRsa pneumonia sub-
jects (modified intent-to-treat) at end of treatment and
end of study. Microbiologic success was also consis-
tent in both the per-protocol and the modified intent-
to-treat groups at both end of treatment and end of
study. overall mortality was 15.7 % for linezolid and
17.0 % for vancomycin.
thrombocytopenia  (linezolid  1.3  %,  vancomycin
2.2 %) and renal failure (linezolid 3.8 %; vancomycin
7.2 %) occurred at relatively low rates.
coNclusIoN
there  is  growing  evidence  that  vancomycin,  despite
low resistance rates is a suboptimal therapeutic option
in  critically  ill  patients,  particularly  in  patients  with
pneumonia. disadvantages of vancomycin are i) slow
bactericide action, ii) poor penetration into pulmonary
tissue,  iii)  the  globally  slowly  increasing  vancomycin
MIcs (“creep”) that result in increased clinical failure
despite  being  susceptible  according  to  defined  break
points  and  iv)  nephrotoxicity.  Vancomycin  has  been
shown to be less effective than β-lactams for the treat-
ment of Mssa infections [26, 67-69] and beta-lactams
should be used when possible. In MRsa infections at
least poor tissue penetration and bactericidal effect can
be improved by combination with rifampin according
to in vitro and animal studies and one prospective ran-
domized controlled trial [38]. However, this approach
has serious limitations such as the risk of emerging of
rifampin resistance and drug interactions.
for  MRsa  pneumonia  current  treatment  options
are  limited.  daptomycin  is  inactivated  by  surfactant
[70, 71] and will not be investigated for pneumonia,
tigecyclin (ﾱ ceftazidim) was significantly inferior to
the  comparator  imipenem  (ﾱ  vancomycin)  in  a
prospective study in patients with nosocomial pneu-
monia [72]. Quinupristin-dalfopristin is approved for
the treatment of MRsa pneumonia in some European
countries, but not in the usa [73]. the ats/Idsa
nosocomial pneumonia guidelines do not recommend
quinupristin-dalfopristin for the treatment of MRsa
pneumonia due to clinical cure rates being lower than
vancomycin in clinical trials [74, 75]. 
In fact, linezolid is currently the only licensed and
well studied alternative to vancomycin in MRsa pneu-
monia. conflicting results of smaller prospective stud-
ies, meta-analysis of these studies and retrospective ob-
servations can now be replaced by the new findings of
the zEPHyR study, advocating the superiority of line-
zolid over vancomycin in proven MRsa pneumonia.
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